|
1) Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, NHLBI/WHO Workshop Report. Bethesda, National Heart, Lung and Blood Institute. April, 2001(Update 2006). GOLD website (www.goldcopd.com), 2006
|
|
|
|
|
2) Slinde F, Gronberg A, Engstrom CP, et al. Body composition by bioelectrical impedance predicts mortality in chronic obstructive pulmonary disease patients. Respir Med. 2005; 99: 1004-9
|
|
|
|
|
3) Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample. Findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med. 2006; 173: 79-83
|
|
|
|
|
4) 吉川雅則. 全身性疾患としてのCOPDにおける栄養評価・対策の臨床的意義. 呼吸. 2004; 23: 67-78
|
|
|
|
|
5) Tomoda K, Yoshikawa M, Itoh T, et al. Elevated circulating plasma adiponectin in underweight patients with COPD. Chest. 2007; 132: 135-40
|
|
|
|
|
|
6) Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J. 2008; 31: 492-501
|
|
|
|
|
|
7) Broekhuizen R, Grimble RF, Howell WM, et al. Pulmonary cachexia, systemic inflammatory profile, and interleukin 1β-511 single nucleotide polymorphism. Am J Clin Nutr. 2005; 82: 1059-64
|
|
|
|
|
|
8) Hopkinson NS, Eleftheriou, Payne J, et al. ＋9/＋9 Homozygosity of the bradykinin receptor gene polymorphism associated with reduced fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr. 2006; 83: 912-7
|
|
|
|
|
|
9) Hopkinson NS, Nickol AH, Payne J, et al. Angiotensin converting enzyme genotype and strength in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 170: 395-9
|
|
|
|
|
|
10) Matsuyama W, Mitsuyama H, Watanabe M, et al. Effects of omega-3 polyunsaturated fatty acids on inflammatory markers in COPD. Chest. 2005; 128: 3817-27
|
|
|
|
|
|
11) Broekhuizen R, Wouters EFM, Creutzberg EC, et al. Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease. Thorax. 2005; 60: 376-82
|
|
|
|
|
|
12) van der Vaart H, Koeter GH, Postma DS, et al. First study of infliximab treatment in patients with in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 172: 465-9
|
|
|
|
|
|
13) Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175: 926-34
|
|
|
|
|
|
14) Fuld JP, Kilduff LP, Neder JA, et al. Creatine supplementation during pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax. 2005; 60: 531-7
|
|
|
|
|
|
15) Deacon SJ, Vincent EE, Greenhaff PL, et al. Randomized controlled trial of dietary creatine as an adjunct therapy to physical training in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008; 178: 233-9
|
|
|
|
|
|
16) 日本呼吸器学会COPDガイドライン第2版作成委員会. In: COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン第2版. 東京: メディカルレビュー社; 2004
|
|
|
|
|
|
17) King DA, Cordova F, Scharf SM. Nutritional aspects of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008; 5: 519-23
|
|
|
|
|
|
18) Kitaguchi Y, Fujimoto K, Kubo K, et al. Characteristics of COPD phenotypes classified according to the findings of HRCT. Respir Med. 2006; 100: 1742-52
|
|
|
|
|
|
19) Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350: 1005-12
|
|
|
|
|
|
20) Ong KC, Earnest A, Lu SJ. A multidimensional grading system (BODE index) as predictor of hospitalization for COPD. Chest. 2005; 128: 3810-6
|
|
|
|
|
|
21) Sergi G, Coin A, Marin S, et al. Body composition and resting energy expenditure in elderly male patients with chronic obstructive pulmonary disease. Respir Med. 2006; 100: 1918-24
|
|
|
|
|
|
22) Budweiser S, Heinemann F, Meyer K, et al. Weight gain in cachectic COPD patients receiving noninvasive positive-pressure ventilation. Respir Care. 2006; 51: 126-32
|
|
|
|
|
|
23) Gan WQ, Man SFP, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systemic review and a meta-analysis. Thorax. 2004; 59: 574-80
|
|
|
|
|
|
24) Agusti A, Morla M, Sauleda J, et al. NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax. 2004; 59: 483-7
|
|
|
|
|
|
25) Langen RCJ, Schols AMWJ, Kelders MCJM, et al. Muscle wasting and impaired muscle regenera-tion in a murine model of chronic pulmonary inflammation. Am J Respir Cell Mol Biol. 2006; 35: 689-96
|
|
|
|
|
|
26) Vernooy JH, Kucukaycan M, Jacobs JA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease. Soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med. 2002; 166: 1218-24
|
|
|
|
|
|
27) van Helvoort HA, Heijdra Y, Thijs HMH, et al. Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc. 2006; 38: 1543-52
|
|
|
|
|
|
28) 吉川雅則, 友田恒一, 木村 弘. COPDの病態と栄養をめぐる新知見. 呼吸. 2007; 26: 421-9
|
|
|
|
|
|
29) Debigare R, Marquis K, Cote CH, et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest. 2003; 124: 83-9
|
|
|
|
|
|
30) Creutzberg EC, Wouters EFM, Vanderhoven-augustin IML, et al. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000; 162: 1239-45
|
|
|
|
|
|
31) Itoh T, Nagaya N, Yoshikawa M, et al. Elevated plasma ghrelin levels in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 170: 879-82
|
|
|
|
|
|
32) Matsumura T, Nakayama M, Satoh H, et al. Plasma orexin-A levels and body composition in COPD. Chest. 2003; 123: 1060-5
|
|
|
|
|
|
33) Mannino DM, Watt G, Hole D, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J. 2006; 27: 627-43
|
|
|
|
|
|
34) Man SFP, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006; 61: 849-53
|
|
|
|
|
|
35) Miyamoto K, Aida A, Nishimura M, et al. Gender effect on prognosis of patients receiving long-term home oxygen therapy. Am J Respir Crit Care Med. 1995; 152: 972-6
|
|
|
|
|
|
36) 吉川雅則, 木村 弘. 呼吸器疾患における栄養管理の実際. 呼吸と循環. 2007; 55: 997-1005
|
|
|
|
|
37) Steiner MC, Barton RL, Singh SJ, et al. Nutritional enhancement of exercise performance in chronic obstructive pulmonary disease: a randomized controlled trial. Thorax. 2003; 58: 745-51
|
|
|
|
|
|
38) Matsuyama W, Mitsuyama H, Watanabe M, et al. Effects of omega-3 polyunsaturated fatty acids on inflammatory markers in COPD. Chest. 2005; 128: 3817-27
|
|
|
|
|
|
39) Broekhuizen R, Wouters EFM, Creutzberg EC, et al. Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease. Thorax. 2005; 60: 376-82
|
|
|
|
|
|
40) Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest. 2005; 128: 1187-93
|
|
|
|
|
|
41) 吉川雅則, 福岡篤彦, 木村 弘. 慢性呼吸不全と栄養管理. 慢性閉塞性肺疾患を中心に. 呼吸と循環. 2005; 53: 279-88
|
|
|
|
|
|
42) Casaburi R, Bhasin S, Cosentino L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 170: 870-8
|
|
|
|
|
|
43) Nissen SL, Sharp RL. Effects of dietary supplements on lean mass and strength gains with resistance exercise: a meta-analysis. J Appl Physiol. 2003; 94: 651-9
|
|
|
|
|